Podcasts about mikhail

In die week se episode #ontnonsens Paul Maritz, Frederik van Dyk, Ernst van Zyl en Reiner Duvenage 'n paar sake van nasionale en internasionale belang - skakel gerus in!

Mikhail Kirichenko is an entrepreneur. He founded the fintech company Jump.Finance, grew it up to multimillion-dollar profits and sold to Tinkoff bank. FIND MIKHAIL ON SOCIAL MEDIA LinkedIn | Facebook ================================ SUPPORT & CONNECT: Support on Patreon: https://www.patreon.com/denofrich Twitter: https://twitter.com/denofrich Facebook: https://www.facebook.com/denofrich YouTube: https://www.youtube.com/denofrich Instagram: https://www.instagram.com/den_of_rich/ Hashtag: #denofrich © Copyright 2022 Den of Rich. All rights reserved.

The orange army waved their flags proudly as they welcomed home favorite, Max Verstappen, to the finish line.  In this episode of racing lines, Mikhail Miranda and Wes Reynolds reaped the Dutch Grand Prix. Sound bites of Lewis Hamilton's frustration during the race were played to outline the strategy mistake by Mercedes which cost Lewis' maiden win of the season. As Lewis and Mercedes are due for a win, Mikhail and Wes outlined the Top 5 Things we learned from the Dutch Grand Prix and spoke about the possibility of Mercedes securing second in the Constructor's Championship. As Las Vegas replays playing host in F1 for 2023, Mikhail talks about the importance of this week's Italian Grand Prix at the Temple of Speed. Tune in to hear more about the betting angles Wes and Mikhail play.See omnystudio.com/listener for privacy information.

Na edição #184 do Sagres Internacional, o jornalista Rubens Salomão e o professor de história e geopolítica Norberto Salomão conversam sobre o falecimento de Mikhail Gorbarchev, último governante da URSS.Confira:

Sovjetunionens sidste leder Mikhail Gorbatjov hyldes især af vestlige ledere som en modig statsmand, der var med til at slutte den kolde krig og lod forandringen blæse gennem de stive sovjetiske systemer. Men mange blev skuffede, fordi reformerne ikke gav dem et bedre liv, kun mere usikkerhed og tomme hylder. Og i dagens Rusland ser mange ham stadig mest som den skyldige i, at Sovjetunionen blev opløst. Friheden i dagens Rusland er meget langt fra 80'ernes reformtid og spraglede kulturelle frisættelse. Men de frø, der blev sået dengang, findes endnu hos en del af befolkningen. Og måske vil eftertiden give Gorbatjov en endnu større plads i historien, også i Rusland. Gæster: Journalist og forfatter Samuel Rachlin, seniorforsker ved Dansk Institut for Internationale Studier Flemming Splidsboel og Charlotte Flindt Pedersen, Dansk Udenrigspolitisk Selskab. Vært: Brita Kvist.

In this episode Mikhail Miranda and Wes Reynolds recap the phenomenal recovery drive of Max Verstappen in the Belgian Grand Prix, how Red Bull and Max are running away with the baton in the championship battles. Pro Tip: Sometimes waiting and doing research, on the number at various books, driver and team strategies, help best in evaluating which bets to make. VSiN has a new fall afternoon lineup stay tune to the end to hear Mikhail outline the new line up.See omnystudio.com/listener for privacy information.

Este 30 de agosto de 2022 falleció Mikhail Gorbachov, el último hombre que cargó el mando de la Unión Soviética. En esta pequeña nota de actualidad les contamos algo de la relevancia histórica de este personaje y el porqué su figura es fundamental para entender el presente de la geopolítica mundial  Notas del episodio: El hombre que siempre trató de evitar una tercera guerra mundial  Lo que Russia Today escribió sobre el fallecimiento de Gorbachov    ¡Síguenos en nuestras Redes Sociales! Facebook: https://www.facebook.com/DianaUribe.fm/ Instagram: https://www.instagram.com/dianauribef... Twitter: https://twitter.com/dianauribefm?lang=es Pagina web: https://www.dianauribe.fm

Mikhail Gorbaciov (o Gorbachev) è morto martedì 31 agosto all'età di 91 anni. L''ultimo leader sovietico è stato ricordato in ogni angolo del pianeta, ma nella sua Russia prevalgono le voci critiche.

edição de 1 setembro 2022

In Tonight's Speech Will Biden Go From Semi Fascist to Full on Fascist in Describing the MAGA Republicans? | Is Fascism in America's Political DNA or Has Trump Brought it Into the Mainstream? | Across the Country Infrastructure is Breaking Down From Underinvestment and Climate Change backgroundbriefing.org/donate twitter.com/ianmastersmedia facebook.com/ianmastersmedia

Yesterday the news broke that Mikhail Gorbachev, former President of the Soviet Union, had died at age 91. He has been hailed by many world leaders for his "remarkable vision", his "impact on the course of world history", and for ending the Soviet Union. But his life converged with 3 great men and women. They were the big 4. Boyd looks at what would have happened if even one of those players hadn't been a part of history at the same time. See omnystudio.com/listener for privacy information.

La morte di Mikhail Gorbaciov – scomparso a 91 anni, martedì 30 agosto – segna l'addio all'ultimo presidente dell'Unione sovietica e segretario del Partito comunista sovietico. In questo podcast, Andrea Romano, deputato del Partito Democratico e docente di Storia contemporanea all'Università Tor Vergata di Roma, approfondisce gli anni di Mikhail Gorbaciov alla guida del Partito comunista sovietico, quelli della riforma prima della dissoluzione dell'Urss.Alla radice degli orientamenti riformatori di Gorbaciov non c'era la democratizzazione dell'Unione sovietica o del PCUS ma semmai il cambiamento – spiega Romano – per prolungare la leadership politica del partito comunista sovietico nel Paese. La perestrojka, la ristrutturazione, e glasnost, trasparenza nelle decisioni, avrebbero dovuto garantire solidità. Così non è stato.

Politicians from all parties are decrying the verbal attack against Deputy Prime Minister Chrystia Freeland. But this is not just an issue affecting politics in Canada. Dr. Robert Huish is an Associate Professor in the Department of International Development Studies at Dalhousie University. He reacts to the video for the first time in this conversation that also reflects on the global impact of former USSR leader Mikhail Gorbachev, who recently passed away.

L'ultimo leader dell'Unione Sovietica Mikhail Gorbaciov è morto all'età di 91 anni. Lo ha annunciato il Central Clinical Hospital della Russia, dove era ricoverato da qualche tempo.

durée : 00:03:30 - La chronique d'Anthony Bellanger - Partout dans le monde, l'annonce du décès de l'ex-président soviétique a suscité des commentaires et des unes.

The Czar talks to the winningest coach in Texas A&M history, RC Slocum. Coach Slocum tells the story about the time he had dinner with two world leaders.

durée : 00:03:30 - La chronique d'Anthony Bellanger - Partout dans le monde, l'annonce du décès de l'ex-président soviétique a suscité des commentaires et des unes.

Morreu nesta terça-feira (30/8) aos 91 anos de idade, em um hospital na capital russa Moscou, Mikhail Gorbachev, último líder da União Soviética (1922 — 1991). O estadista implementou as medidas de transparência política e reestruturação econômica que levaram à extinção do bloco soviético e ao fim do período de Guerra Fria, que se prolongou na segunda metade do século XX, com a oposição dos comunistas ao bloco capitalista liderado pelos Estados Unidos.

mikhail kobzar // @ tapetown.live // 18-06-2022 by TAPETOWN

John Driscoll is a growth hacker, entrepreneur, and the CEO of Naked Development in Irvine California. Connect with John: https://nakeddev.com/ https://www.linkedin.com/in/thejohndriscoll/ Connect with Mikhail: https://www.instagram.com/miqk https://www.mikhailalfon.com https://www.twitter.com/miqk

Tonight Bryce Eddy is joined by the one and only Fadde Mikhail. They discuss a broad range of topics dealing with the epic battle between good and evil for the souls of mankind in these interesting times. To get a FREE info kit on diversifying and protecting your savings with precious metals in a TAX-SHELTERED account text LIBERTY to 989898. BE A THREAT TO THE GREAT RESET! Join our community by Subscribing to us on: Liftable TV - https://watch.liftable.tv/series/XOi2uRcOSGlo-liberty-station Rumble - https://rumble.com/c/c-1611564 YouTube - https://www.youtube.com/channel/UCiXnArqAIXmVLZSSwEyd1HQ Podcast - https://omny.fm/shows/liberty-stationSee omnystudio.com/listener for privacy information.

Tonight Bryce Eddy is joined by the one and only Fadde Mikhail. They discuss a broad range of topics dealing with the epic battle between good and evil for the souls of mankind in these interesting times.To get a FREE info kit on diversifying and protecting your savings with precious metals in a TAX-SHELTERED account text LIBERTY to 989898.BE A THREAT TO THE GREAT RESET!Join our community by Subscribing to us on:Liftable TV - https://watch.liftable.tv/series/XOi2uRcOSGlo-liberty-stationRumble - https://rumble.com/c/c-1611564YouTube - https://www.youtube.com/channel/UCiXnArqAIXmVLZSSwEyd1HQPodcast - https://omny.fm/shows/liberty-station

After 100 minutes of recording, Gordon's Zoom client locks up and the entire episode is lost. Or not. The latest lists doing well in the competitive scene are discussed as well as Gordon and Mikhail's continuing efforts to grow/revitalize X-Wing communities where they live.

It's a hot topic right now to be a media company, but what does it mean to build one? I spoke with someone who is actively doing it to learn more. Mikhail Myzgin, VP Marketing at Slice broke it down with the detail and precision that only he could. It was a true masterclass of an episode.

Josh Boyd is an entrepreneur, investor, and speaker. He currently sits as co-founder and CEO of The 12. Connect with Josh: https://www.instagram.com/joshboyd.12/ https://www.the12.com email: Email Josh Connect with Mikhail: https://www.instagram.com/miqk https://www.mikhailalfon.com

On today's episode, Dennis speaks with Officer Mikhail Brookshire, who on March 17th, 2020 was shot in the head while responding to a call for an active shooter when his rifle jammed. Mikhail shares his story of how the events unfolded, how he was able to stay in the fight and how he has overcome this violent incident both physically and mentally. If you like what you are hearing and want to stay in the loop with the latest in Street Cop Training, please follow our Facebook Page: https://www.facebook.com/StreetCopTraining

Nick learns what sodomy is, Harrison is reduced to tears, and Mikhail's hot takes just get hotter. [GONE BIBLICAL] IG: brownnotblackpodcast Twitter: @_BrownNotBlack Email: brownnotblackpod@gmail.com Music: Молчат Дома (Molchat Doma) - Судно (Sudno) Нет монет - монеточка

Ellen B. Tsai is a business consultant, mentor, and host of the Your Sacred Pattern podcast. Connect with Ellen: https://www.instagram.com/ellie_bt https://www.ellenbtsai.com/ Listen to her podcast here. Connect with Mikhail: https://www.instagram.com/miqk https://www.twitter.com/miqk https://www.mikhailalfon.com

In this episode Mikhail Miranda and Wes Reynolds review the French Grand Prix. Mikhail outlines the "Top 5 Things We Learned" from the French Grand Prix and how that can influence the futures betting market and the odds for the Hungarian Grand Prix. Some breaking news was released prior to the episode recording, which was how Porsche has planned to enter the Formula 1 atmosphere. Tune in to hear more about that. Wes then introduced the betting odds for the Hungarian Grand Prix, and Mikhail revealed how he handicapped the odds for his bets. Mikhail's Bets: Max Verstappen Outright Win +120 Fernando Alonso Top 6 Finish -130 Lando Norris Top 6 Finish +115 Mick Schumacher Points Finish +175 Follow us on twitter for more: @MikhailAMiranda | @WesReynolds1 | @VSiNLiveSee omnystudio.com/listener for privacy information.

This week, please join authors Mikhail Kosiborod and Christian Schulze and Editorialist Stefan Anker as they discuss the original articles "Effects of Empagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial" and "Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)" and the editorial "SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy." Dr. Carolyn Lam:             Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-hosts. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley:           And I'm Dr. Greg Hundley, associate editor, director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Dr. Carolyn Lam:             I'm so excited about the feature discussion this week. It is a paired feature along with their editorial and it's all focused on SGLT2 inhibitors. The first, results from the EMPULSE trial, Effects of Empagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients Hospitalized for Acute Heart Failure; and the second, the EMPAG-heart failure trial, The Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients with Acute Heart Failure. Incredibly important topics, incredibly important discussion. Wait up for it. We're just going to tell you a little bit more about two other original papers in today's issue, and I'm going to go first, Greg. Is that okay? Dr. Greg Hundley:           You bet. Dr. Carolyn Lam:             Now, really interesting topic here. We have strong evidence supporting the effective blood pressure and cardiovascular disease risk lowering properties of healthy diet such as the DASH diet, Mediterranean diet, and so on and so on. But what about the diet consumed by a fifth of the entire world's population? The Chinese cuisine. Interestingly, today's paper addresses just that. This is from authors, Dr. Wu, from Peking University Clinical Research Institute and colleagues who performed a multicenter patient and outcome assessor blind randomized feeding trial among 265 participants with baseline systolic blood pressure of 130 to 159 in four major Chinese cuisines. And these are the Shandong, Huaiyang, Cantonese, and Szechuan cuisines, and here's how they did it. After a seven day run in period on a control diet matching the usual local diets, participants were randomized to continue with the control diet or the cuisine based Chinese heart healthy diet for another 28 days. The primary outcome was systolic blood pressure. The study developed the first heart healthy Chinese diet that fits Chinese food culture and emphasizes its palatability by involving master shifts in developing the recipes. Dr. Greg Hundley:           Oh wow. Carolyn, this is really interesting, especially one fifth of the world's population in studying a heart healthy diet. So did it work? I can't wait to hear the results. Dr. Carolyn Lam:             Well, the change in systolic and diastolic blood pressure from baseline to the end of the study in the control group was five millimeters mercury and 2.8 millimeters mercury reduction, respectively. The net difference of change between the two groups in systolic and diastolic blood pressure were a reduction of 10 and almost four millimeters mercury, respectively. The effect size did not differ among cuisines, and so in summary, with a patient and assessor blind randomized feeding trial, this study really demonstrated that the blood pressure lowering effect of the Chinese heart health diet could indeed be substantial, and importantly, be compatible with medications while palatable and affordable in Chinese adults with high blood pressure, and so these results support the idea that food is medicine and will give many patients with high blood pressure the confidence to adopt heart healthy diets in their lifestyle treatment. Dr. Greg Hundley:           Wow, Carolyn, that is really an interesting article. So many of these articles today could all be features in and of themselves. That was just outstanding. Well, my next paper comes to us from the world of preclinical science, and it's from Dr. Sean Wu from Stanford University School of Medicine. So Carolyn, immune checkpoint inhibitors are monoclonal antibodies that are used to activate the immune system against tumor cells. Now, despite their therapeutic benefits, immune checkpoint inhibitors have the potential to cause immune mediated adverse events such as myocarditis, a rare but serious side effect with up to 50% mortality in affected patients. Now histologically, patients with immune checkpoint inhibitor of myocarditis have lymphocytic infiltrates in the heart implicating T-cell mediated mechanisms. However, the precise pathologic immune subsets and molecular changes in immune checkpoint inhibitor myocarditis are unknown. Dr. Carolyn Lam:             Wow. So insights into the etiology of these immune checkpoint associated myocarditis cases must be very important. So what did they find? Dr. Greg Hundley:           Right, Carolyn? So clonal cytotoxic, TEMRA CD8+ cells were found to be significantly increased in the blood of patients with immune checkpoint inhibitor myocarditis corresponding with an analogous increase in effector cytotoxic CD8+ cells in the blood and hearts of PD-1 deficient mice with myocarditis. These expanded effector CD8+ cells had unique transcriptional changes, including upregulation of the chemokines CCL5, CCL4, and CCL4L2, and they may serve as attractive diagnostic therapeutic targets for reducing life threatening cardiac immune related adverse events in immune checkpoint inhibitor treated cancer patients, and Carolyn, just like so many of our articles, there's a very nice accompanying editorial by Professor Gianluigi Condorelli that also offers an update on current research pertaining to non-systemic steroid therapy to treat immune mediated myocarditis. Well, Carolyn, how about we jump to some of the other articles in the issue? Dr. Carolyn Lam:             Oh, you bet, Greg. There's an exchange of letters between Drs. Madias and Knops regarding the article “Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: The Analysis of All Appropriate Therapy in the PRAETORIAN Trial.” Dr. Greg Hundley:           And also in the mail bag, Professor Mark has a Research Letter entitled “Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction, The SUGAR-DM-HF Study,” and our own Tracy Hampton has several synopses from articles published elsewhere in our piece on cardiovascular news. Well, how about we get onto that feature forum discussion, two papers, two editorialists. I can't wait. Dr. Carolyn Lam:             Me too. Let's go, Greg. Dr. Greg Hundley:           Welcome, listeners to this July 26th feature forum discussion. So remember, listeners, for forum discussions, we have several manuscripts that focus on a singular topic and we bring together the authors, our associate editors, and also an editorialist, and today, I want to introduce, we have with us Dr. Mikhail Kosiborod from Mid America Heart Institute in Kansas City, Missouri, Dr. Christian Shults from University Hospital Jena in Germany, Stefan Anker from Charité in Berlin, Germany, and our Associate Editors, Brendan Everett from Brigham and Women's Hospital in Boston, Massachusetts, and Justin Grodin from University of Texas Southwestern Medical Center in Dallas, Texas. Welcome, gentleman, and we'll start with you, Mikhail. Could you describe for us the background information that went into the preparation of your study and what was the hypothesis that you wanted to address? Dr. Mikhail Kosiborod:   Well, thanks very much, Greg. The background for the study, which was the secondary analysis of the EMPULSE trial was patients that are hospitalized with acute decompensated heart failure represent a very high risk group. We know that they have high risk of death and hospitalizations, and we also know that they have very poor health status that's very high burden of symptoms, physical limitations, and poor quality of life, and so addressing those treatment goals, trying to reduce the risk of clinical events like death and hospitalizations and improve the symptoms and physical limitations in this patient population are very important treatment goals. Now we previously demonstrated in the main results of the EMPULSE trials that using empagliflozin initiating empagliflozin SGLT2 inhibitor in this patient population as compared with placebo provided a significant total clinical benefit, which was a composite of total death, repeat hospitalizations for heart failure, or a change in a Kansas City cardiomyopathy questionnaire, which is a kind of a gold standard measure of patient's health status. What we tried to do in a much more granular fashion in this study is to understand the effects of empagliflozin as compared with placebo on this very important outcome, the Kansas City cardiomyopathy questionnaire, and we actually evaluate all of the key domains and composite symptoms, physical limitations, as well as quality of life. Dr. Greg Hundley:           Very nice, and Mikhail, can you describe for us what study population specifically, and then what was your study design? Dr. Mikhail Kosiborod:   Well, this was a population of patients that were hospitalized with heart failure and that EMPULSE was unique in its design because first of all, previous SGLT2 inhibitor trials mostly focused on patients with chronic heart failures that were in an outpatient setting, including prior trials of empagliflozin, and EMPULSE really focused on acutely hospitalized patient population, but it included patients regardless of ejection fraction. So as they were hospitalized with decompensated heart failure and reduced or preserved ejection fraction. They were enrolled regardless of if they had type 2 diabetes, they were enrolled essentially, regardless of kidney function, only patients with EGFR of less than 20 were excluded, and also importantly, was this study and a unique feature of the study in particular was that we enrolled patients whether they had acute de novo heart failure. That means that was a new diagnosis of heart failure that was bad enough for them to be hospitalized or worsening chronic heart failure requiring hospitalization. So it was really an all-comer trial for patients acutely hospitalized for heart failure. So we had just over 500 patients and they were randomized in the hospital. After a brief period of stabilization, we use empagliflozin, 10 milligrams daily or placebo and treated for 90 days, and the primary outcome at 90 days was a total clinical benefit that I described that was a composite, hierarchical composite of total death hospitalizations, repeat hospitalizations for heart failure and changing KCCQ. In this study, again, we focused predominantly on KCCQ, trying to understand the effects on health status, again, symptoms, physical limitations, and quality of life. Dr. Greg Hundley:           Excellent. And Mikhail, what were your study results? Dr. Mikhail Kosiborod:   Well, what we observed, a couple of things. One is we first examined the effects of empagliflozin on the primary endpoint across the range of KCCQ and baseline, and what we found was that regardless of the degree of symptomatic impairment and baseline, empagliflozin was consistent in providing them total clinical benefits that I described previously, and then kind of shifting to what I think is the most interesting findings, the effects of empagliflozin versus placebo on KCCQ, what we found was that as you would imagine in this population of patients that were acutely hospitalized with heart failures, that had very poor health status, very low KCCQ at baseline, and within the first 90 days, which was observation period, both groups of patients had substantial improvements in KCCQs. As one would expect after acutely decompensated episode of heart failure and treatment in a hospital, everyone got better. But patients treated with empagliflozin had significantly greater improvement in KCCQs than those that were treated with placebo, and that was first of all, a very substantial difference between the two groups. It was more than five points in favor of empagliflozin already at 15 days and was highly statistically significant, and it was maintained throughout the 90 day treatment period. So the fact that we saw both a clinical meaningful and statistically significant improvement in just 15 days, I think is a very important clinical message, and then finally, I guess what I will mention is these benefits of empagliflozin while main outcome we looked at was KCCQ total symptoms, we're focusing on the symptoms, but it was consistent when we looked at physical limitations as well as quality of life. So really, all key domains of KCCQ were impacted in a similar way. Dr. Greg Hundley:           Very nice. So in acute heart failure, marked symptomatic improvement after the administration of the SGLT2 inhibitor empagliflozin at 10 milligrams per day. Well, now listeners, we're going to turn to our associate editor, Dr. Brendan Everett, and Brendan, again, you have many papers come across your desk. What attracted you to this particular manuscript? Dr. Brendan Everett:      Well, thanks, Greg, and I think this manuscript caught my eye because of the importance of the clinical question, and Mikhail outlined why I think that was really relevant. So we understand that this class of medications or SGLT2 inhibitors have important effects on outcomes like re-hospitalization in patients with heart failure, and what was particularly striking about this paper is that it took patients rather than those with chronic heart failure, but as Mikhail mentioned, enrolled a patient population that was actually in the hospital, and I think this was an important frontier for this particular question about when to start the SGLT2 inhibitor and what kind of benefits there might be. Furthermore, I think the fact that they did not select the population based on ejection fraction was particularly striking, and of course, I think is remarkable, but now old news, they did not select on the presence or absence of diabetes as well. And so those three components really attracted me to the paper. I also think the outcome is one that really is valuable and worth exploring, and specifically, I'm talking about how patients feel on the medication after a hospitalization for heart failure. Appropriately, we focused on re-hospitalization for heart failure and cardiovascular death in prior trials in this space, and I think we need to embellish those findings or further deepen those findings with a perspective on how patients actually feel when they get the medication, and of course, it goes without saying that what's particularly important here also is that it was a randomized placebo controlled trial, and so the results have some element of internal validity that I think is really important. So those were the things, Greg, that really attracted my attention as I read the paper for the first time. Dr. Greg Hundley:           Thank you so much, Brendan. Well, listeners, we've got a second paper today and we're next going to hear from Dr. Christian Shults, and he also is focusing on really another aspect of the administration of empagliflozin in patients with acute heart failure and that pertains to the renal function of the patients. So Christian, could you describe for us the background pertaining to your study and what was the hypothesis that you were intending to address? Dr. Christian Schulze:     Thanks, Greg. Well, it's great to introduce all study here in this running. So our study impacted those in acute decompensated heart failure. The impact HF trial was a study based on the hypothesis that we wanted to test, whether empagliflozin has effects in acute decompensated heart failure, and we focused on the patient population that was not addressed in EMPULSE, patients that came to the ER and needed to be treated right away, and we wanted to know and this was our main hypothesis, but are the diuretic and [inaudible 00:17:11] effects of the SGLT2 inhibitor on this case, empagliflozin, actually had an impact on diuretic regimens and kidney functions since this is one of the main end points that limits treatment, and also is one of the outcomes of patients with acute decompensated heart failure in the hospital. Dr. Greg Hundley:           Very nice. And so Christian, what study design did you implement and who was included in your study population? Dr. Christian Schulze:     So we also used the randomized two arm study design. We included patients with acute decompensated heart failure independent of left ventricular ejection fraction. Patients needed to have an NT-proBNP of more than 500. The average NT-proBNP in fact was 4,300 in our entire patient population, and we included patients within 12 hours of presentation. So many of these patients have been recruited in the ER, they presented two hour cardiology heart failure service, and then were immediately randomized to the trial in the two arms, and we tested not 10 milligrams of empagliflozin. We actually tested 25 milligrams of empagliflozin based on in-house data that 25 milligrams potentially had a stronger diuretic effect compared to 10 milligrams. Dr. Greg Hundley:           And what did you find? Dr. Christian Schulze:     So we followed patients for five days. It was a relatively short period of time. It was designed to address the in-house phase of patients with acute decompensated heart failure. The mean duration of stay was 6.3 days in the hospital so this was exactly the time that we wanted to test. We had a 30 day endpoint for safety issues, and what we could see is that patients on 25 milligrams on empagliflozin on top of standard diuretic regimens and medical care had 25% higher diuretic outputs compared to patients in the placebo group. We also found no differences in markers of renal injury dysfunction, and could in fact confirm that after 30 days, patients in the empagliflozin group had a better EGFR compared to patients in the placebo group. On top, we saw a more rapid decrease in body weight and also a more profound decrease in NT-proBNT values. Dr. Greg Hundley:           And Christian, just for our listeners to put a little bit of this in perspective, what was the range of serum creatinine for the patients that were enrolled in your study? Dr. Christian Schulze:     So the main EGFR in the entire population was around 60 and the creatinine values were around 107 on average in the entire cohort. So this is a very typical population. We had around 30% of the population with de Novo heart failure, around 20 to 30% of the population was pre-treated for preexisting heart failure. So very typical population of patients with heart failure presenting to the emergency room. Dr. Greg Hundley:           And did you have any kind of lower level EGFR cutoff, I mean, for enrollment into this study? Dr. Christian Schulze:     So when we designed the trial, we actually still had the sub classification of diabetes or impaired glucose or homeostasis as an inclusion criteria. We dropped it before we started the trial because the data came out that this is actually, in fact, not a critical issue for patients with heart failure. So diabetes was not a subgroup in our trial and the lower limit of EGFR was actually a thoroughly defined protocol. Dr. Greg Hundley:           Very nice. Well, listeners, now we're going to turn to our second associate editor, Dr. Justin Grodin from University of Texas Southwestern Medical Center in Dallas, Texas, and Justin, similar to Brendan, and you see many papers come across your desk and so what attracted you to this particular paper by Christian and his colleagues? Dr. Justin Grodin:            Well, Greg, I think first and foremost, and I think very similar to Brendan, but I think what's always striking is if I may just take a step back, decompensated heart failure in the United States is the number one cause for hospitalization among Medicare beneficiaries. So I think really, the brunt and really the truly public health message of the disease is very important in the applicability, and even though that decompensated heart failures is one of the most common things that we ever encounter when we practice, internists, cardiologists, et cetera, we have very, very little clinical trial guidance that tells us how to decongest individuals when they're hospitalized with swelling and heart failure and a lot of these individuals can be quite ill, and we have some clinical trial data, but largely, we have a lot of negative studies or inconclusive studies in this space. So certainly, what drew me to this trial was definitely that context, and obviously, based on the mechanistic data with SGLT2 inhibitors, I think one of the natural questions, which Christian addresses, is that we know that up front, they do augment natriuresis. So I think it's very compelling to marry those two together because this is what many of us that use these medications regularly have been asking is whether or not they would have some efficacy in that regard, and then another thing that caught my eye and me as a cardiorenal investigator was, just as Christian highlighted, was we have a clinical trial that randomly assigned individuals, really that were ill and many of whom were not stabilized within 12 hours of presentation, and we're talking about patients that are coming into the hospital at all times during the day in and I think that's very remarkable that we have something with standard... We have a study with standardized assessments where we're really trying to ask a very practical, pragmatic question, which is do these therapies lower the sodium balance in individuals with decompensated heart failure, and I think what's important is largely, we've got a lot of medications that supplement loop diuretics, which are the class of drugs that the majority of us use, and we have a lot of other therapies that we use that really have very little data or poor data that guide us such as thiazide diuretics, carbonic and hydrase inhibitors, mineralocorticoid receptor antagonists, and so here, we have a clinical trial that asks a question that's on many people's minds. And then we do have very compelling, at least short term pragmatic and mechanistic data that does tell us that these individuals do have a greater natriuretic effect when empagliflozin is used as an adjunct to standardized loop diuretic therapy. So it's a very practical clinical question, and I think what's very important, and we could debate probably all day about the implications of GFR change and kidney function change while we're decongesting somebody with diuretics, but I think what's reassuring to all the clinicians is we really didn't see an effect on kidney function despite a greater natriuretic effect or enhanced diuretic effect, if you will, with the use of empagliflozin. Dr. Greg Hundley:           Very nice. Well, thank you, Justin. Listeners, now we have an editorialist and as you know, editorialists really help us put the scientific presentation of an original manuscript into the perspective of really the global theme of a topic, and we have Stefan Anker from Berlin, and Stefan, can you describe for us how do we put these two manuscripts and results that we've heard about really in the context now of moving forward with the use of SGLT2 inhibitors in the management of patients with acute decompensated heart failure? Dr. Stefan Anker:            Thank you so much. Really, I think these two papers, on the one hand, enhance our certainty about early use, and on the other hand, possibly show us that there might be even more to achieve by, on the one hand, moving even earlier with the application of SGLT2 inhibitors or possibly consider the higher dose. Now let's take one step back. These drugs were developed in type two diabetes and the first successful trial was the [inaudible 00:25:42] outcome trial. Many people have forgotten that this trial tested two doses and not only one, the 10 and the 25 milligram dose, and of course, with the success for improving kidney outcomes and heart failure hospitalization outcomes, we move forward into these two specialist areas, on the one hand, broadening it to the non-diabetic communities, but on the other end, narrowing it by focusing on the 10 milligram dose regardless of whether there is [inaudible 00:26:12]. And we basically now learn A, to use these drugs even earlier than we did in the big trials and we can now be sure to start their use in the hospital, and if you take the average change in quality of life results seen, you actually get a better result for the patient on quality of life when you start earlier than when you start late in the ambulatory studies where basically, in the chronic setting, maybe you have one and a half to two points difference. Here, you now have four and a half points in the study shown by Mikhail, and of course, it's also good to know that you can start this in any type of patient, regardless of their quality of life. The impact study from Christian, they basically moved it now even earlier, moving into the hospital space is possible based on EMPULSE. Moving it into the acute admission space is at least a consideration now based on what Christian here has shown. And he is actually addressing the one question I hear very often in my presentations about SGLT2 inhibitors, what about this 25 milligram dose? Is there a place for this in cardiology as well, and a possible place is shown here, not only that this is a safe thing to do, but also you get urinary output. Of course, we may in the future, want to see this compared, directly compared to the 10 milligram dose, but of course, the world is not created in one day, but needs more than one and so really, I think these two studies, on the one hand, address an important issue, when to start using them. On the other hand, show us a little bit of a glimpse to the future. Dr. Greg Hundley:           Very nice, Stefan, and listeners, we get to take advantage of having these authors, editors, and editorialists together and ask them what they see as the next study to be performed in this sort of sphere of research. So Mikhail, we'll start with you. In 30 seconds or less, what do you see as the next study to be performed in this arena of research? Dr. Mikhail Kosiborod:   I think, Greg, what we've learned recently, including from the EMPULSE trial, we have this population of patients in a hospital with heart failure's a huge issue as Justin mentioned, and until recently, we had very little [inaudible 00:28:31] for them beyond the usual kind of decongestion with loop diuretics and trying to make them feel better, but you look at outcome data. It really was a dearth of effective therapies that have meaningful impact on important outcomes. Now that's changing, SGLT2 inhibitors is one example. There are some other recent examples in this patient population, like a firm HF and iron deficient patients with heart failure. But the bottom line is it's no longer kind of a desert, if you will, of positive trials. We now have something we can do and I think what this proves is that we need to actually invest more, both in terms of resources and time to really do what we we're being able to do in other areas of heart failure and those patients with chronic, half and half where we can start developing pillars of therapy that can actually truly improve outcomes with this patient population and there is a lot going on that makes me optimistic that's going to be the case in the coming years. Dr. Greg Hundley:           Very nice. And Brendan? Dr. Brendan Everett:      Well, I think both trials mentioned today really pushed our understanding of this population forward. I think the biggest clinical question that I face when I'm caring for these patients is that we have four, at least, guideline directed therapies, right? We have beta blockers, we have ARBs, ACE inhibitors and ARNIs. We have mineral receptor antagonists and we have SGLT2 inhibitors. So which do we use in what order and how do we start them, and what kind of parameters do we use to guide us if we're limited either by renal function or by blood pressure or by some other factor. And we often, if not always, have one of those constraints that we're dealing with and so I would say the next step for me is trying to sort out which of these therapies and what order ought to be our highest priority for patients with acute decompensated heart failure as we move quickly from the acute decongestion stage towards discharge and a chronic therapy that will then be followed as an outpatient over the ensuing days and months. Dr. Greg Hundley:           Very nice. And Christian. Dr. Christian Schulze:     Thank you again, and Brandon pointed out very nicely. I mean, we have good evidence now for chronic heart failure treatment. We have the four columns of heart failure medical therapy. Questions that remain open is what do we do with all these patients that are now guideline medicated, come to the hospital with an acute decompensation? Should we carry on with the medication? Should we terminate and in particular, should be carry on with full dose, 50% dose of SGLT2 inhibitors, and the next question is, what dose should we use, in fact, for SGLT2 inhibitors? Is it in group effects or is sotagliflozin comparable to empagliflozin, and then is there a role for a step by scheme that we initially have in high dose therapy that we then downgrade to 10 milligrams on the chronic heart failure treatments, and then of course, quality of life is very important. We should ask this question also in this patient population that is early on treated, do we see benefits that carry on in the outpatient setting and do we see an effect of early treatment on long term benefits? Dr. Greg Hundley:           Justin? Dr. Justin Grodin:            Well, I would have to agree with all of my colleagues here on this call. I think all have raised really good points, but I think one very simple, and I'll echo some of Brendan's statements, but one very simple question is we know that when we decongest people and initiate a negative salt balance in the hospital for decompensated heart failure, we cause neurohormonal activation and there are a lot of downstream untoward effects from chronic decongestive therapies, and I think one of the more compelling things is we still yet have defined what is the best way to decongest individuals with swelling or volume overload in the hospital. Here, we have compelling studies with SGLT2 inhibitors for quality of life and really, the way patients feel. And this is really what's important to them, and then something very pragmatic to clinicians and let's make people pee more, but I think one of the compelling questions, and I don't know if it will be answered, is we have a lot of choices for supplemental therapies and different diuretic strategies when patients come in the hospital for decompensated heart failure, and I do think that these studies do move the needle with SGLT2 inhibitors. I think that's abundantly clear, but we still don't know what is the best way to dry out my patient or make my patient pee so that they feel better, but I do think that these studies do at least set the stage that there's some compelling advantages to SGLT2 inhibitors. Dr. Greg Hundley:           And then lastly, Stefan. Dr. Stefan Anker:            Thank you. Besides the detailed points mentioned by many, and Christian, totally support 25 versus 10 milligram, how long 25 milligram, if at all in the future. Besides this, I'm interested in the big picture question. So what about the post myocardial infarct congestion/heart failure situation, and there will be two trials in the next 18 to 24 months that report on this, and my pet kind of area is actually to treat heart failure where nobody thinks it is heart failure, and what I mean is for instance, advanced cancer patients, cardiac wasting cardiomyopathy. So the heart failure in sick cancer patients, and indeed, we are planning to do exactly that now in a study focusing on hospice care patients to really improve the quality of life, the very thing focus here on the EMPULSE trial. Dr. Greg Hundley:           Well, listeners, we want to thank our authors, Dr. Mikhail Kosiborod from Mid America Heart Institute in University of Missouri, and Christian Shults from the University Hospital in Jena, Germany. Also, our associate editors, Dr. Brendan Everett from Brigham and Women's Hospital in Boston, and Dr. Justin Grodin from University of Texas Southwestern in Dallas, Texas, and also, our editorialist, Dr. Stefan Anker from Charité in Berlin, Germany for bringing us these two manuscripts pertaining to two randomized clinical trials regarding the administration of the SGLT2 inhibitor, empagliflozin in acute heart failure, demonstrating first, marked improvement in heart failure symptoms and health related quality of life. And second, in those with estimated GFRs greater than 30 mls per minute, an augmentation of natriuresis in the setting of the co-administration of diuretics without deterioration in renal function. Well, on behalf of Carolyn and myself, we want to wish you a great week and we will catch you next week on the run. This program is copyright of the American Heart Association, 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

Is this the part where the alphabet agencies start listening to our show too? Russian-born Mikhail joins the pod and gets into topics I'd be better off not putting into writing. Music: музыка из фильма „ ДЖЕНТЛЬМЕНЫ УДАЧИ ” Rasputin - Boney M. Part 1 of a 2 part episode IG: brownnotblackpodcast Twitter: @_BrownNotBlack Email: brownnotblackpod@gmail.com

In this episode of Racing Lines, Mikhail Miranda and Wes Reynolds preview the French Grand Prix.  First they review the Austrian Grand Prix, with Mikhail highlighting the Top 10 things we learned from the Grand Prix which can be carried forward to the French Grid Prix giving context to what bettors could witness from teams and drivers. Mikhail's Bets: Max Vertstappen Outright Win +115 Charles Leclerc Outright Win +130 Mick Schumacher Points Finish +105 See omnystudio.com/listener for privacy information.

00:00 - Singing 02:21 - Good Morning 02:32 - Introduction 14:50 - Sponsors 17:29 - Amud Aleph 40:10 - Amud Beis 57:48 - Have a Wonderful day -- Today's shiur is sponsored לע״נ יוסף ברוך בן משה אהרון & לע״נ משה אלעזר בן נטע שלום And for the hatzlacha בכל ענינים for my children & Jeff Rosner: in zchus of my son Yosef Simcha Chaim Ben Sarah Refuah Shlaima & The Lock and Lebovic families, Lakewood NJ because Torah is the best segula! & Refuah Shilayma for חנה יוכבד אביה בת שפרה חיה & the MDY Family Leilu Nishmas Shimshon Weiss - Shimson ben Meshulam Dov z'l Shimmy.8MinDaf.com & As a zechus for our children to be kadosh, safe, healthy, happy & know השם loves them & I should be זוכה to נחת דקדושה And have tremendous success in my new business & Nisim Akilov: In Honor Of Rav Eli Thank You For Bringing Us All Together Here Tonight! & Aaron Akilov: In Honor Of Rav Eli! & Nisim Akilov: In Honor Of My Father, Pinkhas, Zalman, Sion, Mikhail, Aaron, Gavriel, & Avram Moshe & Learning Kesubos as a zechus for a shidduch for Eliezer Noam ben Yitzchak Meir & the Boyer family: לעילו נשמת ר׳ אליהו ז״ל ב״ר אברהם נ״י Who passed away the shabbos after the last event in NY. He loved MDY and was proud to be a part of it --- Turning of the daf Sponsored by Moshie Horn in honor of Rabbi Tzvi Medetsky, the only Rebbe that was actually good at basketball… & Nesanel: L'hatzluche Ruchny and gashmy for Murad Nakash, For introducing me to MDY

Timestamps: 6:26 - MBAs aren't just for managers 12:22 - Covering any distance in less than 2h 15:43 - When hydrogen will become cheaper 24:34 - Building a hyperplane prototype in 4 months 29:33 - Dealing with aviation regulation About Mikhail Kokorich: Mikhail Kokorich is the founder and CEO of Destinus, an aerospace company building hyperplanes to provide the fastest transportation on earth. He studied business administration back in Russia and also went on to complete executive programs at Stanford, and co-founded several companies such as Astro Digital, Exact Farming and Momentus. Founded in 2021, Destinus is developing an extremely fast aircraft capable of moving cargo between continents in 1-2 hours. This vehicle will be a hybrid between an airplane and a rocket— they call it a hyperplane. It runs on hydrogen, which allows you not only to build incredibly powerful engines but also to cool them, so that overheating does not become an issue at that type of speed. Hydrogen-fueled hyperplanes are also carbon neutral. Hydrogen is not yet affordable, but from his talks with hydrogen producers Mikhail estimates that within 3-5 years, some selected airports will have it available at a reasonably low price; in 5-10 years, almost any airport will have it; and after 10 years it will hopefully become one of the primary fuels for aviation. After having built their first prototype in just 4 months, Destinus estimates that within 3 years a hyperplane MVP will be available for testing, but not yet for commercial use — for that they require certification. In the meantime their MVP will allow them to start generating some revenue and prove customer interest. Memorable Quotes: "With Hyperplanes, you will be able to fly to Tokyo to have dinner with your friends, fly back afterwards and sleep in your own bed." "In ten years' time hydrogen will hopefully become one of the main fuels for aviation." Resources Mentioned: Y Combinator If you would like to listen to more episodes about aviation, check out our conversations with André Borschberg and Patrick Thevoz. Don't forget to give us a follow on our Twitter, Instagram, Facebook and Linkedin accounts, so you can always stay up to date with our latest initiatives. That way, there's no excuse for missing out on live shows, weekly give-aways or founders dinners!

Medical marijuana has been in use for the last few decades as an alternative to help with anxiety, pain, inflammation, sleep, and more. Nevertheless, it can be confusing to understand how and when to use it. Today's guest, Dr. Mikhail Kogan, is here to help us demystify medical marijuana and discuss its origins, uses, and precautions. Dr. Kogan is Medical Director of GW Center for Integrative Medicine, an associate director of the Geriatrics Fellowship Program and is associate director of newly formed GW Interdisciplinary Integrative Medicine Fellowship. He also recently published a book Medical Marijuana: Dr. Kogan's Evidence-Based Guide to the Health Benefits of Cannabis and CBD. Don't miss this discussion with Dr. Kogan about the benefits of medical marijuana and what you need to know before using it. Timestamps: 0:00 - Introduction 4:17 - History of cannabis 11:24 - What conditions can cannabis be helpful for? 18:29 - Interactions between CBD and medications? 20:52 - Legal categorizations of cannabis 25:20 - Neurodegenerative conditions 31:41 - Cannabis for anxiety, depression, and PTSD 35:05 - Dosing cannabis 38:28 - Training for clinicians 43:45 - Laws in different areas and how to access 49:25 - How to learn more and work with Dr. Kogan

Watch the video version: https://www.youtube.com/watch?v=kTcJqThCdns Topics covered ----------------------------- - Guests introduction - Plan - Merge transition - Ethereum today - Bellatrix, Consensus Layer - Paris, Execution Layer - Merge transition - Terminal total difficulty vs. block number - TTD hits before Bellatrix - TTD override - Merge rollout - Questions - How confident devs are that we do not have to do TTD override for the mainnet Merge? - What would be the difference in activation time in terms of hrs./days/weeks between Bellatrix & Paris. - Is it simple or difficult to estimate the activation time? - PoS post Merge - Client diversity - Running a node - Saving the Planet - Ultrasound money - Priority fees - Block confirmations - Finalized and safe blocks - RANDAO - Stable block times - Transaction fees - Withdrawals - Proof of Execution - Resources - what if a beacon chain validator goes offline for any reason just before the transition and gets online after the merge has already occurred on the mainnet? Can the validator get back on the right chain? Is there any penalty/slashing proposed for such validators? Resources: ----------------- Slides: https://docs.google.com/presentation/d/1g5pTIVNuiVU0h654_jTQbwcZ0RbcsL-CNOMuCmzfbk8 EIP-4399 with Mikhail Kalinin - https://youtu.be/wwfOqmCbPNU PEEPanEIP playlist - https://www.youtube.com/playlist?list=PL4cwHXAawZxqu0PKKyMzG_3BJV_xZTi1F EIP-3675 with Mikhail Kalinin - https://youtu.be/zNIrIninMgg The Merge playlist - https://www.youtube.com/playlist?list=PL4cwHXAawZxqoLxXqZqT4hcYhoHoP6w12 Check out upcoming EIPs in Peep an EIP series at https://github.com/ethereum-cat-herders/PM/projects/2 Follow at Twitter ----------------------------------------------- Mikhail Kalinin @mkalinin2 | Pooja Ranjan @poojaranjan19 Contact Ethereum Cat Herders --------------------------------------------------- Discord: https://discord.io/EthCatHerders Twitter: https://twitter.com/EthCatHerders Medium: https://medium.com/ethereum-cat-herders GitHub: https://github.com/ethereum-cat-herders Website: https://www.ethereumcatherders.com/

Areli G. is a mother, wife, and athlete for the Buff Bunny Collection and Tc1Gel.  In this episode we explore how focusing on her deep work has impacted her relationships, career, and business ventures.  Connect with Areli on Instagram here. Connect with Mikhail on Instagram here

Mikhail Ryss, from his youth was fond of programming and radio electronics, which led him to the Faculty of Mechanics and Mathematics. The technical background prevails, most of which is associated with software development. More than once I had to conquer terra incognito, explore previously unfamiliar areas, conceptualize ideas into something capable of implementation - from a catalog of active tours to a mosaic laying robot. Most of the initiatives did not pass natural selection, but those in which it was possible to maintain high involvement, somehow survived. Visionary (heaven) considers its own stronger quality than entrepreneurship (earth). U project - arose about 2 years ago, since then he has been all in on it, there are many difficulties, but Mikhail believes that this is the quintessence of his life experience, captivating deeper and deeper. FIND MIKHAIL ON SOCIAL MEDIA LinkedIn ================================ SUPPORT & CONNECT: Support on Patreon: https://www.patreon.com/denofrich Twitter: https://twitter.com/denofrich Facebook: https://www.facebook.com/denofrich YouTube: https://www.youtube.com/denofrich Instagram: https://www.instagram.com/den_of_rich/ Hashtag: #denofrich © Copyright 2022 Den of Rich. All rights reserved.

The Trident Room Podcast host Michael Gannon sits down with Dr. Mikhail Auguston – they discuss Monterey Phoenix and the importance of behavior modeling. This episode was recorded on September 03, 2021. Dr. Mikhail Auguston is an Associate Professor in the Computer Science Department at the US Naval Postgraduate School. Website: http://faculty.nps.edu/maugusto/ Research by Auguston: https://nps.academia.edu/MikhailAuguston Monterey Phoenix: https://wiki.nps.edu/display/MP/Monterey+Phoenix+Home The Trident Room Podcast is brought to you by the Naval Postgraduate School Alumni Association and the Naval Postgraduate School Foundation. npsfoundation.org For comments, suggestions, and critiques, please email us at TridentRoomPodcastHost@nps.edu, and find us online at nps.edu/tridentroompodcast. Thank you! The views expressed in this interview are those of the individuals and do not reflect the official policy or position of the U.S. Government, the Department of Defense, the US Navy, or the Naval Postgraduate School.

The Trident Room Podcast host Michael Gannon sits down with Dr. Mikhail Auguston – they discuss Monterey Phoenix and the importance of behavior modeling. This episode was recorded on September 03, 2021. Dr. Mikhail Auguston is an Associate Professor in the Computer Science Department at the US Naval Postgraduate School. Website: http://faculty.nps.edu/maugusto/ Research by Auguston: https://nps.academia.edu/MikhailAuguston Monterey Phoenix: https://wiki.nps.edu/display/MP/Monterey+Phoenix+Home The Trident Room Podcast is brought to you by the Naval Postgraduate School Alumni Association and the Naval Postgraduate School Foundation. npsfoundation.org For comments, suggestions, and critiques, please email us at TridentRoomPodcastHost@nps.edu, and find us online at nps.edu/tridentroompodcast. Thank you! The views expressed in this interview are those of the individuals and do not reflect the official policy or position of the U.S. Government, the Department of Defense, the US Navy, or the Naval Postgraduate School.

In this episode of Racing Lines, Mikhail Miranda and Wes Reynolds preview the Azerbaijan Grand Prix. They recap the craziness that occurred during the Monaco Grand Prix, and the crazy long shot that Mikhail hit with Sergio Perez winning at 12/1. Tune in to hear what Mikhail and Wes think about Ferrari, Red Bull, and Lewis Hamilton's performance clause for Mercedes. Mikhail's Bets: Charles Leclerc Outright Win +175 Sergio Perez Outright Win +650 Valtteri Bottas Points Finish -310 Kevin Magnussen Points Finish +115 Carlos Sainz Podium Finish +120 *ODDS VIA BOYD GAMING Wes' Bets: Charles Leclerc Outright Win +205 *ODDS VIA DRAFTKINGS SPORTSBOOKS See omnystudio.com/listener for privacy information.

Mikkail is cheating on his wife with his end escorts, married men and more and he called in to talk all about it. When did he start cheating? Do his hook-ups always remain sexual? And, has he ever had an emotional affair as well? Tun in for all the details including why he's never had a monogamous relationship, how his cheating gives him a rush that he enjoys and can't live without, when he realized he had a foot fetish, how he stumbled upon his first adult bookstore and wound up in a glory hole, how far he went in the glory hole, his experience picking up a trans prostate and how hot that experience was, how he met men through Craigslist and how most of them were married, what he enjoys doing with men, his hook-ups with random women while traveling for work, the married guy who lives in his building who he is hooking up with and a whole lot more. To hear his groping his wife's best friend video and my view of that whole scenerio, click here: https://youtu.be/9UQS4k_cPaA Sponsor: Hottest stories on Dipsea, 30 day FREE TRIAL https://www.dipseastories.com/strictlyanon To see anonymous pics of most of most my female guests + get early access to the show + get ad free episodes and anonymous confessions, join my Patreon, it's only $5 a month. You can sign up here: https://www.patreon.com/StrictlyAnonymousPodcast Want to be on the show? Email strictlyanonymouspodcast@gmail.com or go to http://www.strictlyanonymouspodcast.com and click on "Be on the Show." Have something quick you want to confesss? Call the hotline at 347-420-3579. Your voice will be changed, so you remain anonymous. Follow me! Youtube https://www.youtube.com/c/StrictlyAnonymouspodcast Instagram https://www.instagram.com/strictanonymous/ Twitter https://twitter.com/strictanonymous?lang=en Everything else https://linktr.ee/Strictlyanonymouspodcast Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Mikhail Miranda and Wes Reynolds preview the Monaco Grand Prix. We introduce the episode with a recap of the Spanish Grand Prix; how Red Bull Racing issued team orders to swap the positions of their drivers, and the calamity that Ferrari's driver, Charles Leclerc, faced. Mikhail and Wes, previewed the Monaco circuit, and what you might expect from the drivers. Whether or not Charles Leclerc can overturn his curse of not finishing his home Grand Prix? And how Mercedes have made major gains in their upgrade. Odds and lines are presented by Draftkings Sportsbook and are subject to change. Bets made by Mikhail were established through Boyd Gaming. See omnystudio.com/listener for privacy information.

In this episode of Racing Lines, Mikhail Miranda and Wes Reynolds preview the Spanish Grand Prix. We have a quick recap of the Miami GP, and current standings with their respective odds, and then we dive right into the Spanish Grand Prix. A plus for today's episode is Mikhail finally revealed his secret bet...a wager on an Alfa Romeo driver. See omnystudio.com/listener for privacy information.

Charters Wynn's book The Moderate Bolshevik: Mikhail Tomsky from the Factory to the Kremlin, 1880-1936 (Brill, 2022)is English-language biography of Mikhail Tomsky. It reveals Tomsky's central role in all the key developments in early Soviet history, including the stormy debates over the role of unions in the self-proclaimed workers' state. Charters Wynn's compelling account illuminates how the charismatic Tomsky rose from an impoverished working-class background and years of tsarist prison and Siberian exile to become both a Politburo member and the head of the trade unions, where he helped shape Soviet domestic and foreign policy along generally moderate lines throughout the 1920s. His failed attempt to block Stalin's catastrophic adoption of forced collectivization of agriculture would tragically make Tomsky a prime target in the Great Purges. Listen in! Samantha Lomb is a lecturer at Vyatka State University in Kirov, Russia. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/history

Charters Wynn's book The Moderate Bolshevik: Mikhail Tomsky from the Factory to the Kremlin, 1880-1936 (Brill, 2022)is English-language biography of Mikhail Tomsky. It reveals Tomsky's central role in all the key developments in early Soviet history, including the stormy debates over the role of unions in the self-proclaimed workers' state. Charters Wynn's compelling account illuminates how the charismatic Tomsky rose from an impoverished working-class background and years of tsarist prison and Siberian exile to become both a Politburo member and the head of the trade unions, where he helped shape Soviet domestic and foreign policy along generally moderate lines throughout the 1920s. His failed attempt to block Stalin's catastrophic adoption of forced collectivization of agriculture would tragically make Tomsky a prime target in the Great Purges. Listen in! Samantha Lomb is a lecturer at Vyatka State University in Kirov, Russia. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In this episode of Racing Lines, Mikhail Miranda and Wes Reynolds preview the Spanish Grand Prix. We have a quick recap of the Miami GP, and current standings with their respective odds, and then we dive right into the Spanish Grand Prix. A plus for today's episode is Mikhail finally revealed his secret bet...a wager on an Alfa Romeo driver. See omnystudio.com/listener for privacy information.

Michael Mikhail is the Founder and CEO of Stratton Equities, the nation's leading hard money and NON-QM lender to national real estate investors, with the largest variety of mortgage loans and programs under one roof.  Having launched Stratton Equities in early 2017, Michael has always been an entrepreneur and innovator in the real estate market, purchasing his first home at 19 utilizing hard money.   He is a serial entrepreneur with a foresight for business opportunities.  He officially joined the mortgage industry in 2003 and decided to travel to explore his options globally.  After traveling to 19 countries in 5 years, Michael knew two things; he wanted to start his own business and launch it in the United States.  In 2017, Michael noticed how the mortgage industry had transformed after the regulations presented from 2008-2012, and knew it was time to set out something on his own, thus creating Stratton Equities. Under Michael's leadership, Stratton Equities has grown into one of the biggest leaders in the Mortgage and Real Estate industry across genres and platforms.   [00:01 – 06:20] Opening Segment Michael is a private money lender, has ADHD, and has always been creative and passionate about what he does Get to know how Michael began his business career at the age of 15   [06:21 – 16:47] Master Entrepreneurship Be Aggressive in Your Business What it means to be “selfish for yourself to find success” Michael's growing pains in 2008 and 2009 The need to have a product that people are interested in and the need to spend money on marketing to get the product into the hands of consumers   [16:48 – 24:50] Learning from Mistakes Michael started a vitamin company, failed but learned from it If a business does not make money at first, it is still possible to learn and succeed in the long run Treat people well, have a clear vision, and respect the people around you   [24:51 – 34:00] Closing Segment Quick break for our sponsors The first step to growing your wealth is tracking your wealth, income spending and everything else about your finances, you can start tracking your wealth for free and get six free months of wealth advisor.  Learn more about Personal Capital at escapingwallstreet.com What is the best investment you've ever made other than your education? Equities Michael's worst investment No bad investment, but stepping stones to move on to the next one What does success mean to you? “You can't build anything alone.” Connect with Michael Mikhail through https://www.strattonequities.com/. Invest passively in multiple commercial real estate assets such as apartments, self storage, medical facilities, hotels and more through https://www.passivewealthstrategy.com/crowdstreet/ Participate directly in real estate investment loans on a fractional basis. Go to www.passivewealthstrategy.com/groundfloor/ and get ready to invest on your own terms. Join our Passive Investor Club for access to passive commercial real estate investment opportunities. LEAVE A REVIEW + help someone who wants to explode their business growth by sharing this episode or click here to listen to our previous episodes                     Tweetable Quotes: “People have to be a part of your vision to scale.” – Michael Mikhail “It's not about the money. You can't say, like Elon Musk and say, I want to make all this money. It was what he was passionate about, what he did and what he had a knack for.” – Michael Mikhail